Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia

Gilteritinib induces 2 distinct marrow responses in FLT3-mutated AML: responses with and without differentiation. Ongoing clonal hematopoiesis is ubiquitous during gilteritinib therapy and may promote genetic evolution and drug resistance.

Sparad:
Bibliografiska uppgifter
I publikationen:Blood Adv
Huvudupphovsmän: McMahon, Christine M., Canaani, Jonathan, Rea, Bryan, Sargent, Rachel L., Qualtieri, Julianne N., Watt, Christopher D., Morrissette, Jennifer J. D., Carroll, Martin, Perl, Alexander E.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Hematology 2019
Ämnen:
Stimulus Report
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6538870/
https://ncbi.nlm.nih.gov/pubmed/31122910
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018029496
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk